We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+58.2%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$160M
AUM Growth
+$53.9M
Cap. Flow
+$1.45M
Cap. Flow %
0.91%
Top 10 Hldgs %
86.01%
Holding
55
New
3
Increased
9
Reduced
6
Closed
1

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$996K
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$437K
3
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$364K
4
AMRN
Amarin Corp
AMRN
+$343K
5
MYGN icon
Myriad Genetics
MYGN
+$304K

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$737K
2
ATRA icon
Atara Biotherapeutics
ATRA
+$372K
3
VCYT icon
Veracyte
VCYT
+$267K
4
SITO
SITO MOBILE, LTD
SITO
+$168K
5
AMAG
AMAG Pharmaceuticals
AMAG
+$152K

Sector Composition

Rank Sector Weight
1 Healthcare 96.8%
2 Energy 2.17%
3 Consumer Staples 0.09%
4 Materials 0.08%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYTK icon
51
Cytokinetics
CYTK
$10.7B
$81K 0.05%
10,000
– –
SITO
52
DELISTED
SITO MOBILE, LTD
SITO
$73K 0.05%
40,000
-100,000
-71% -$168K
GNMX
53
DELISTED
Aevi Genomic Medicine Inc
GNMX
$25K 0.02%
128,000
– –
WKHS icon
54
Workhorse Group
WKHS
$30.1M
$15K 0.01%
8
– –
AMAG
55
DELISTED
AMAG Pharmaceuticals
AMAG
– –
-10,000
Closed -$152K
1 2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2019 Portfolio in Review

As of Q1 2019, Birchview Capital held 55 positions worth $160M, up 51% from $106M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Birchview Capital's Q1 2019 filing shows 3 new, 9 increased, 6 reduced and 1 closed positions. Its largest new stake was Bristol-Myers Squibb: 20,000 shares worth $954K. The largest sale was Soleno Therapeutics, an estimated $737K.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q1 2019 buy was Bristol-Myers Squibb: 20,000 shares worth $954K.
  • Birchview Capital added most to Intercept Pharmaceuticals, Inc. in Q1 2019, an estimated $437K increase.
  • Birchview Capital's biggest Q1 2019 reduction was Soleno Therapeutics, cutting an estimated $737K.
  • Birchview Capital fully exited AMAG Pharmaceuticals in Q1 2019, selling an estimated $152K.
  • Birchview Capital's ten largest holdings make up 86% of its $160M portfolio in Q1 2019.
  • Birchview Capital opened 3 new positions and closed 1 in Q1 2019.
  • Birchview Capital's portfolio value rose 51% quarter-over-quarter to $160M.

Based on Birchview Capital's 13F filing for Q1 2019, filed 3 May 2019.